These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33984530)

  • 1. Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel GG; Dhami R; Baxter M; Kosar J; Cervera C; Irfan N; Zvonar R; Borgia S; Tessier JF; Dow G; Ariano R; Dube M; Savoie M; Bassetti M; Walkty A; Karlowsky JA
    J Glob Antimicrob Resist; 2021 Jun; 25():346-350. PubMed ID: 33984530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
    Pogue JM; Kaye KS; Veve MP; Patel TS; Gerlach AT; Davis SL; Puzniak LA; File TM; Olson S; Dhar S; Bonomo RA; Perez F
    Clin Infect Dis; 2020 Jul; 71(2):304-310. PubMed ID: 31545346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
    Martin-Loeches I; Bruno CJ; DeRyke CA
    Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry.
    Zhanel G; Baxter M; Wong M; Mirzanejad Y; Lee A; Dhami R; Kosar J; Werry D; Irfan N; Tessier JF; Girourd G; Tascini C; von den Baumen TR; Walkty A; Karlowsky JA
    J Glob Antimicrob Resist; 2023 Jun; 33():171-176. PubMed ID: 37030573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies.
    Chi Y; Xu J; Bai N; Liang B; Cai Y
    Expert Rev Anti Infect Ther; 2023 Feb; 21(2):189-201. PubMed ID: 36629486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ; Chahine EB; Cogan P; Fete M
    Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
    Shortridge D; Duncan LR; Pfaller MA; Flamm RK
    Int J Antimicrob Agents; 2019 May; 53(5):637-643. PubMed ID: 30716448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry.
    Zhanel GG; Kosar J; Baxter M; Dhami R; Borgia S; Irfan N; MacDonald KS; Dow G; Lagacé-Wiens P; Dube M; Bergevin M; Tascini C; Keynan Y; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2021 Mar; 24():335-339. PubMed ID: 33540083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
    J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against
    Shortridge D; Pfaller MA; Arends SJR; Raddatz J; DePestel DD; Flamm RK
    Open Forum Infect Dis; 2019 Jun; 6(6):ofz240. PubMed ID: 31263733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
    Pfaller MA; Shortridge D; Arends SJR; Duncan LR; Streit JM; Flamm RK
    Diagn Microbiol Infect Dis; 2020 Sep; 98(1):115101. PubMed ID: 32622289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C; Solomkin J
    Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
    Scott LJ
    Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane-tazobactam: When, how and why using it?
    López Montesinos I; Montero M; Sorlí L; Horcajada JP
    Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):35-37. PubMed ID: 34598422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
    Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
    Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.